EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19

EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19

Research in the development of new therapeutic agents with a wide spectrum of the antiviral activity and a low ability to develop resistance remains the main dimension in combating the global threat to public health. The need for a parenteral form of favipiravir was dictated by the necessity to incr...

Full description

Saved in:

Bibliographic Details
Main Authors:	L. A. Balykova, K. Ya. Zaslavskaya, V. F. Pavelkina, N. A. Pyataev, N. M. Selezneva, N. V. Kirichenko, A. Yu. Ivanova, G. V. Rodoman, K. B. Kolontarev, K. S. Skrupsky, E. N. Simakina, O. A. Mubarakshina, A. V. Taganov, D. Yu. Pushkar
Format:	Article
Language:	Russian
Published:	Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2022-03-01
Series:	Фармация и фармакология (Пятигорск)
Subjects:	favipiravir covid-19 sars-cov-2 novel coronavirus infection areplivir
Online Access:	https://www.pharmpharm.ru/jour/article/view/1034
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

STUDY OF LONG-TERM CLINICAL AND PATHOGENETIC EFFECTS OF FAVIPIRAVIR-BASED ANTI-VIRAL DRUG IN PATIENTS WITH METABOLIC SYNDROME IN POST-COVID PERIOD
by: O. A. Radaeva, et al.
Published: (2022-05-01)

STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT
by: L. A. Balykova, et al.
Published: (2021-12-01)

Phase I Pharmacokinetics Study of Drug for Infusion «Areplivir» (INN: Favipiravir) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2023-05-01)

Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2024-03-01)

EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19)
by: L. A. Balykova, et al.
Published: (2020-12-01)

Reciprocal Impact of Molnupiravir and Favipiravir Monocomponents of the Combination Drug on Each Other's Pharmacokinetics in a Phase I Clinical Trial
by: T. N. Komarov, et al.
Published: (2024-03-01)

Development and Validation of HPLC-UV Method for the Determination of Favipiravir in Human Plasma
by: T. N. Komarov, et al.
Published: (2022-09-01)

Determination of Favipiravir in Human Blood Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-09-01)

Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
by: Abdullah Sayiner, et al.
Published: (2022-03-01)

Efficacy of favipiravir in COVID-19: A retrospective two center comparative study
by: Elif Tukenmez Tigen, et al.
Published: (2024-09-01)

A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
by: Yu. V. Shevchuk, et al.
Published: (2025-02-01)

Simultaneous Determination of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) and Favipiravir in Human Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-02-01)

Pharmacogenetic Markers of Favipiravir Safety in COVID-19 Treatment
by: I. I. Temirbulatov, et al.
Published: (2023-10-01)

CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY
by: D. N. Zemskov, et al.
Published: (2022-12-01)

Efficacy and safety of remdesivir and favipiravir in COVID-19 patients – A systematic review and meta-analysis
by: Piyush Vatsha, et al.
Published: (2025-05-01)

The Evaluation of Patients with Severe COVID-19 Pneumonia Who are Recieving Favipiravir Treatment
by: Servet ÖZTÜRK, et al.
Published: (2021-12-01)

A Retrospective Analysis of Treatment of Covid-19 with Favipiravir
by: Aigul Utegenova, et al.
Published: (2022-06-01)

Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters
by: Megan Neary, et al.
Published: (2024-11-01)

Prevalence of AOX1 and CYP1A2 gene polymorphisms associated with response to favipiravir therapy in novel coronavirus infection COVID-19 among ethnic groups of the North Caucasus
by: A. T. Leinsoo, et al.
Published: (2025-07-01)

The safety and adverse event profile of favipiravir in the treatment of COVID-19 patients, Turkey
by: Elif Tukenmez Tigen, et al.
Published: (2023-11-01)

Antiviral and anti-inflammatory activities of favipiravir and quinine sulfate against dengue virus serotype 1 in vitro
by: Regita Aulia Rosalina, et al.
Published: (2025-03-01)

Investigating the Effectiveness of Superchlorination and Fenton Processes in Removing Hydroxychloroquine and Favipiravir from Synthetic Wastewater
by: Narjes Yaghoubi, et al.
Published: (2025-02-01)

Discovery of novel favipiravir derivatives with improved pharmacokinetic properties as anti-SFTSV agents
by: Xiaomeng He, et al.
Published: (2024-12-01)

Physicochemical Properties and Molecular Insights of Favipiravir and Roflumilast Solid Dispersions for COVID-19 Treatment
by: Abdul Rauf, et al.
Published: (2025-04-01)

Comparative Analysis of the Antiviral Activity of Various Drugs Based on 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide (Favipiravir) Against COVID-19
by: S. Ya. Loginova, et al.
Published: (2024-06-01)

Andrographis paniculata or favipiravir in Mild COVID-19: A randomized control trial
by: Rujipas Sirijatuphat, et al.
Published: (2025-08-01)

Preparation, and ex vivo and in vivo Characterization of Favipiravir-Loaded Aspasomes and Niosomes for Nose-to-Brain Administration
by: Salamah M, et al.
Published: (2025-05-01)

A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients
by: Kai Yang, et al.
Published: (2022-09-01)

Eco-sustainable chromatographic method for the determination of favipiravir and nitazoxanide for COVID-19: application to human plasma
by: Amal B. Ahmed, et al.
Published: (2025-01-01)

MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
by: L. A. Balykova, et al.
Published: (2022-10-01)

Case Report: Successful treatment of severe fever with thrombocytopenia syndrome associated with hemophagocytic lymphohistiocytosis by preemptively using favipiravir and methylprednisolone
by: Liang Qiao, et al.
Published: (2025-06-01)

EFFICACY AND SAFETY OF ORIGINAL DRUG BASED ON HEXAPEPTIDE SUCCINATE IN COMPLEX COVID-19 THERAPY IN ADULTS HOSPITALIZED PATIENTS
by: L. A. Balykova, et al.
Published: (2023-02-01)

A quality-by-design optimized LC method for navigating degradation kinetics and quantification of favipiravir in the presence of degradation products and manufacturing impurities
by: Adel Ehab Ibrahim, et al.
Published: (2025-08-01)

Analysis of cytokine response characteristics and immunopathogenetic effects of double-stranded sodium salt RNA-based drug for postexposure prophylaxis against novel coronavirus infection: double-blind, placebo-controlled trial
by: O. A. Radaeva, et al.
Published: (2023-08-01)

Analysis of the Distribution Pattern of Genetic Biomarkers of Safety of Etiotropic Drugs for the Treatment of COVID-19 in Representatives of Ethnic Groups of the Volga Region and the Far East
by: S. N. Tuchkova, et al.
Published: (2025-02-01)

The Estimation of Efficacy of Nonspecific Medications Against Hemorrhagic Fevers Caused by Arenaviruses
by: Т. Е. Sizikova, et al.
Published: (2023-12-01)

Post-exposure prophylaxis of COVID-19: results of double-blind, placebo-controlled, multicenter clinical study evaluation of efficacy and safety of double-stranded sodium salt RNA drug
by: L. A. Balykova, et al.
Published: (2023-05-01)

Cardiotoxic Drugs Used in the Treatment of COVID-19
by: A. S. Zmitrukevich, et al.
Published: (2024-01-01)

The Impact of Coronavirus Disease-19 on Pregnancy Outcomes, A Case Series
by: Bilge Cetinkaya Demir, et al.
Published: (2023-03-01)

The importance of outpatient etiotropic therapy in patients hospitalized with COVID-19
by: Zh. Zh. Zhanibekov, et al.
Published: (2023-04-01)